MDxHealth: Shareholder Transparency Declaration

NEWS RELEASE  
        REGULATED INFORMATION
                INSIDE INFORMATION

MDxHealth: Shareholder Transparency Declaration 

HERSTAL, BELGIUM and IRVINE, CA- January 17, 2018 - MDxHealth SA (Euronext: MDXH.BR) today announced that, that it received the following notification of significant shareholdings, in conformity with Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market.
Shareholdings after actively crossing the transparency threshold:
Capfi Delen Asset Management informed MDxHealth on January 15, 2018 that, as of January 10, 2018, its participation in MDxHealth decreased below the threshold of 3% of the outstanding shares. Capfi Delen Asset Management now owns 1,490,000 shares, i.e. 2.98 %, of the outstanding shares of MDxHealth, a decrease of 32,000 shares compared to the previously reported participation of 3.05%. Capfi Delen Asset Management is a Belgian Management Company of UCITS. For further information, reference is made to the information published on MDxHealth's website (http://www.mdxhealth.com/investors/shareholder-information).

About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, the Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth. 

For more information: 

Jean-Marc Roelandt, CFO
MDxHealth
BE:+32 4 257 70 21
[email protected]

LifeSpring LifeSciences Communication
Leon Melens 
+31 6 538 16 427
[email protected]

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respecti

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/45146ca5-7201-4449-b1e3-933ddbe0b953

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/54f940c9-45cf-45b7-98be-023c9e6a17c1

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/e9e6f474-c574-4112-a716-d82957e2073c